Similarly, CRISPR/Cas9-engineering of CAR T-cells to upregulate Wnt pathway signaling rescued TP53-mutant AML cell sensitivity and led to improved killing efficacy. The gene discussed is TP53; the disease is acute myeloid leukemia.